• Articles
• Financial
• HEALTH

Welcome to our web site

Cures provides the latest articles, news, and website links to help with financial and health related problems.

Synthetic Production of HGH

In August 1996, the FDA approved HGH for use in adult patients. In earlier years, it was authorized strictly for use to promote growth in HGH-deficient kids. The newer indicated condition is somatotropin (growth hormone) deficiency syndrome (SDS), produced from pituitary disease, hypothalamic disease, surgery, radiation therapy, or injury.

In effect, the FDA approval indicates the use of HGH for anti-aging treatment since low levels of HGH or IGF-1 indicate a failure of the pituitary to release enough of this vital substance. additionaly, the signs of SDS, such as losing physical mobility, lost energy, and higher risk of cardiovascular disease, are exactly the same as those indicators seen in aging adults with lower HGH levels. The FDA approval for HGH in older population means that doctors may now prescribe injectable HGH to their patients without fear of practicing outside of mainstream medicine.

Presently, HGH is produced in the lab by genetic engineering methods, generating bio-identical HGH injections. For this reason, it is extremely safe for human use. The HGH injections are similar to that of insulin-very small needles or hi-tech air shots deliver HGH subcutaneously. Most patients find it easy to do and pain free. While different doctors use different dosage shots, the usual somatropin amount is between 2 and 8 IUs per week (1 milligram equals 3 IUs, or international units).

Many doctors specializing in anti-aging regenerative endocrinology are now dividing daily HGH injections into two per day, one in the morning and one at night, to more closely resemble the way HGH is released in the pituitary. The result is to raise the levels of IGF-1 to point levels at age thirty to forty, which for most men and womenis in the high 200s to low 300s.

In June 2000, Genetech, Inc. and Alkermes, Inc. produced the first long-acting medical marijuana form of recombinant human growth hormone. It began shipping medicine to the pediatric endocrine community in the United States upon FDA approval on December 23, 1999. The long-acting formulation of HGH is formed by embedding growth hormone in biodegradable microspheres of polyactive co-glycolide (PLG) microspheres, which allow the HGH to be produced in a bio-identical active form. Following subcutaneous HGH injection, bio-identical growth hormone is released from the microspheres into the blood initially by diffusion, followed by polymer degradation. This formulation of HGH increases patient health as well as compliance by reducing the number of injections needed for growth hormone therapy. Genetech, Inc. reports that it is pursuing FDA approval for use of this product in the treatment of growth hormone(HGH) deficiency in older adults.